Novacyt - Public Comps and Valuation Multiples

Novacyt Overview

About Novacyt

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, IT-IS International, Lab21 Products, Corporate, Yourgene Health and Intercompany eliminations. Majority of the revenue is generated from Yourgene Health segment.

Founded

2006

HQ

Employees

234

Website

novacyt.com

Sectors

Medical Imaging & Diagnostics
Laboratory Services
HealthTech

Financials

LTM Revenue $26.3M

LTM EBITDA -$11.3M

EV

$15.2M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Novacyt Financials

As of December 2025, Novacyt reported last 12-month revenue of $26.3M and EBITDA of -$11.3M.

In the same period, Novacyt achieved -$19.9M in LTM net income.

See Novacyt valuation multiples based on analyst estimates

Novacyt P&L

In the most recent fiscal year, Novacyt reported revenue of $22.8M and EBITDA of -$39.8M.

Novacyt expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Novacyt valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$26.3M	XXX	$22.8M	XXX	XXX	XXX
Gross Profit	n/a	XXX	$37.2M	XXX	XXX	XXX
Gross Margin	n/a	XXX	163%	XXX	XXX	XXX
EBITDA	-$11.3M	XXX	-$39.8M	XXX	XXX	XXX
EBITDA Margin	-43%	XXX	-175%	XXX	XXX	XXX
EBIT	-$14.7M	XXX	-$19.3M	XXX	XXX	XXX
EBIT Margin	-56%	XXX	-85%	XXX	XXX	XXX
Net Profit	-$19.9M	XXX	-$48.5M	XXX	XXX	XXX
Net Margin	-76%	XXX	-213%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Novacyt including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $26.3M. EBITDA for the last twelve months was -$11.3M. In the most recent fiscal year, Novacyt achieved $22.8M in revenue and -$39.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$26.3M	Analyst estimates available to subscribers	$22.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	n/a	Analyst estimates available to subscribers	$37.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	n/a	Analyst estimates available to subscribers	163.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$11.3M	Analyst estimates available to subscribers	-$39.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-42.9% EBITDA margin	Analyst estimates available to subscribers	-174.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$14.7M	Analyst estimates available to subscribers	-$19.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-55.8% EBIT margin	Analyst estimates available to subscribers	-84.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$19.9M	Analyst estimates available to subscribers	-$48.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-75.6% net profit margin	Analyst estimates available to subscribers	-212.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Novacyt

This financial data table provides comprehensive performance metrics for Novacyt, a company based in France. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Novacyt generated $26.3M in revenue over the last twelve months.
The company achieved -$11.3M in EBITDA over the last twelve months.
Net income over the last twelve months reached -$19.9M.

Fiscal Year Performance

In the most recent fiscal year, Novacyt reported $22.8M in total revenue.
Fiscal year EBITDA was -$39.8M.
The company maintained a gross profit margin of 163.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was -174.8%.
Net profit margin reached -212.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Novacyt. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Novacyt Stock Performance

Novacyt has current market cap of EUR 27.8M (or $32.3M), and EV of EUR 13.1M (or $15.2M).

Market Cap Evolution

Novacyt Stock Data

As of January 19, 2026, Novacyt's stock price is EUR 0 (or $0).

See Novacyt trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$15.2M	$32.3M	XXX	XXX	XXX	XXX	$-0.21

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Novacyt Valuation Multiples

Novacyt's trades at 0.6x EV/Revenue multiple, and -1.3x EV/EBITDA.

See valuation multiples for Novacyt and 15K+ public comps

Novacyt Financial Valuation Multiples

As of January 19, 2026, Novacyt has market cap of $32.3M and EV of $15.2M.

Equity research analysts estimate Novacyt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Novacyt has a P/E ratio of -1.6x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$32.3M	XXX	$32.3M	XXX	XXX	XXX
EV (current)	$15.2M	XXX	$15.2M	XXX	XXX	XXX
EV/Revenue	0.6x	XXX	0.6x	XXX	XXX	XXX
EV/EBITDA	-1.3x	XXX	-1.3x	XXX	XXX	XXX
EV/EBIT	-1.0x	XXX	-1.0x	XXX	XXX	XXX
EV/Gross Profit	n/a	XXX	n/a	XXX	XXX	XXX
P/E	-1.6x	XXX	-1.6x	XXX	XXX	XXX
EV/FCF	-1.0x	XXX	-1.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Novacyt Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Novacyt Margins & Growth Rates

Novacyt's last 12 month revenue growth is 15%

Novacyt's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Novacyt's rule of 40 is -143% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novacyt's rule of X is -6% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Novacyt and other 15K+ public comps

Novacyt Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	15%	XXX	16%	XXX	XXX	XXX
EBITDA Margin	-43%	XXX	-43%	XXX	XXX	XXX
EBITDA Growth	-21%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-143%	XXX	-28%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	-6%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.2M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	14%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	248%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial